Apple—another technology darling—dipped 2.5 percent on Monday, bringing its losses this year to more than 6 percent. At about $103 per share, Apple looks like a strong play on valuation, said trader Tim Seymour, who owns the stock.
Read MoreSo, just how bad was Monday's market carnage?
Trader Steve Grasso agreed, saying the stock was "definitely a buy" at that price.
Acorda Therapeutics skidded 3 percent in Monday's session. The stock, though, spiked 30 percent in extended trading on news that two patent challenges to one of its drugs were denied.
Adami believes investors should hold on to Acorda, as it could reach $40 per share in the coming days. Shares closed at about $29 Monday.
Read MoreAfter-hours buzz: Solar City, Charter Communications & more
Tim Seymour is long AAPL, T, BAC, DIS, F, GE, GM, GOOGL, INTC, JPM, Tim's firm is long BABA, BIDU, MCD, NKE, NOK, SBUX, YHOO.
Grasso is long AAPL, BA, BAC, CC, DD, DIS, DECK, EVGN, FIT, KBH, MJNA, MU, PFE, PHM, T, TWTR, GDX. His kids are long EFA, EFG, EWJ, IJR, SPY. His firm and some of its partners are long DVN, BP, COP, CVX, FCX, NE, NEM, OXY, RIG, VALE
Guy Adami is long CELG, EXAS, INTC, Guy Adami's wife, Linda Snow, works at Merck.